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Abstract   
 
Background:  Posttraumatic stress disorder (PTSD) is a form of anxiety disorder that arises after 
exposure to a traumatic event or stressor. It is characterized by persistent invasive thoughts, 
emotional detachment, hypervigilance and sleep disturbances.   These sleep disturbances include 
nightmares, insomnia and distressed awakenings and are often refractory to multiple 
medications, including SSRIs, which are the only FDA approved medication for PTSD. Prazosin 
is an alpha-1 adrenergic antagonist that has been studied for use in nighttime symptoms of PTSD 
in civilian populations, however most data exists for its use in combat-related PTSD.  This 
review examines the differences in these two populations and investigates the off-label use of 
prazosin for sleep disturbances in noncombat posttraumatic stress disorder. 
Methods:  Exhaustive search of available medical literature via MEDLINE, CINAHL, PILOTS, 
and PsychINFO databases using combinations of the terms PTSD, Stress Disorder, Prazosin,  
Alpha Antagonist and Alpha Blocker.  Inclusion criteria were set to incorporate studies that used 
prazosin to treat nighttime symptoms of PTSD in a noncombat, non-military population. 
Exclusion criteria eliminated studies pertaining to combat PTSD, military or veteran population. 
Non peer-reviewed Letters to Editor were also excluded. 
Results:  Four studies, including one randomized control trial, one retrospective cohort, one case 
series and one case study were found. 
Conclusion:  Prazosin has potential as a treatment for the sleep disturbances of noncombat 
related PTSD. Both the prevalent female gender and heterogeneity of individual traumas in this 
civilian population were much different than previous trials and reviews that examined combat 
PTSD.  While the demographics and experiences were diverse compared to the veteran 
population, the positive response to prazosin was similar to past findings. While larger, 
randomized and placebo-controlled trials are needed for FDA approval, the current off-label use 
of prazosin is demonstrated in the existing literature as efficacious. 
Keywords:  prazosin, stress disorder, PTSD, nightmares, alpha antagonist, alpha blocker 
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The Off-Label Use of Prazosin for Sleep Disturbances in Noncombat 
Posttraumatic Stress Disorder 
 
 
BACKGROUND 
 
Posttraumatic stress disorder (PTSD) is an anxiety disorder that arises after exposure to a 
traumatic event or stressor. It is characterized by persistent invasive thoughts, emotional 
detachment, hypervigilance and sleep disturbances.1 PTSD was first recognized in the military 
population and throughout history has often been described as related to combat.2 However, with 
the frequent exposure to trauma to which civilians from the general population are exposed, the 
prevalence of PTSD outside the combat population has greatly increased. Approximately 5.2 
million adults suffer from PTSD throughout a given year, and the estimated lifetime prevalence 
of PTSD is 7.8%.3,4 
 
Sleep Disturbances 
70-87% of those with PTSD develop sleep disturbances, including nightmares, insomnia, 
and distressed awakenings.5,6 Of the wide array of PTSD symptoms, these are some of the 
hardest to treat and are often refractory to multiple medications and treatment modalities. 
Furthermore, the Food and Drug Administration (FDA) currently only approves the use of the 
selective serotonin reuptake inhibitors (SSRIs) sertraline and paroxetine for use in PTSD.7 
Unfortunately, both of these medications have shown little improvement in sleep related 
symptoms and, in some cases can worsen sleep and increase arousals due to their known 
stimulating effects on sleep.7   
 
 
Rating Scales and Assessments 
 Several methods have been developed for assessing posttraumatic stress disorder and the 
array of commonly experienced symptoms. Those found in the following studies will be 
discussed here. The Diagnostic and Statistics Manual, 4th Edition, Text Revision (DSM-IV-TR) 
specific criteria for the diagnosis of PTSD, including exposure to a traumatic event (Criterion A), 
persistent re-experiencing (Criterion B), avoidance of stimuli and numbing of responsiveness 
(Criterion C), hyper-arousal (Criterion D), symptoms lasting for at least one month (Criterion E) 
and a significant impairment of functioning (Criterion F).8 The PTSD Checklist-Civilian Version 
(PCL-C) is an evaluation of symptoms that relies on self report, and when used in combination 
with the DSM-IV criteria, can be a sensitive and specific diagnostic tool.9 The Clinician 
Administered PTSD Scale (CAPS) is a widely accepted method for assessing posttraumatic 
stress disorder as it incorporates a 30 item review of all PTSD symptoms.  Item #2 (“recurrent 
distressing dreams”) and item #13 (“difficulty falling asleep/ staying asleep”) are common 
measurements of sleep-related symptoms of PTSD.  CAPS has also been modified to include a 
Non-Nightmare Distressed Awakenings (NNDA) scale.10 Also more specific is the CAPS One 
Week Symptom Version (CAPS-SX) that combines a nightmare rating with an insomnia rating 
to measure intensity and frequency of these symptoms. To differentiate between pathologic and 
normal dream content, the PTSD Dream Rating Scale (PDRS) was developed for the civilian 
population.  Improvement in nightmares after treatment is measured with the Clinical Impression 
of Change-Nightmares (CIC-N) scale. On a broader spectrum, changes and improvement of 
overall PTSD are often measured via the Clinical Global Impression-Change (CGI-C) score and 
Clinical Global Impression-Improvement (CGI-I) scores, respectively.  One study uses several 
variations of objective measures of Rapid Eye Movement (REM), with use of a portable device, 
called REMView, that patients use at home.10 
 
Prazosin 
Prazosin is a peripherally and centrally acting alpha antagonist that has been most often 
studied for the use of sleep-related symptoms of PTSD in the combat and veteran populations.11-
14 While traditionally used for the treatment of hypertension and benign prostatic hypertrophy, 
prazosin is believed to be effective due to the blocking activity of central alpha adrenergic 
receptors, which are often excessively active in PTSD patients.7 Fewer studies have involved 
populations outside the military, leading to less information regarding the use of prazosin for 
noncombat PTSD sleep symptoms. The differences in these two populations abound.  
The populations differ in gender. Military populations are predominantly male, and thus, 
studies from this population inherently trend toward males.15 In fact, six out of the seven studies 
that were included in a recent systematic review of prazosin use for PTSD were performed in a 
combat or military veteran population, therefore 98% of the patients included in the review were 
male (see Figure 2).7  In contrast, in the general population, there is approximately a 2 to 1 
female to male ratio for PTSD.16 Women are more likely than their male counterparts to have a 
post-traumatic stress response and the overall prevalence of PTSD is higher.17,18 There are 
important differences between males and females in PTSD. After a trauma, women are more 
likely to develop PTSD.  Furthermore, depression as a co-morbidity, longer recovery times, and 
higher prevalence of long-lasting PTSD are all characteristic of PTSD in females when 
compared to males.17  When we look outside the military and examine a more female dominated 
sample, we see PTSD with a different perspective.  
Secondly, the details of the trauma experiences differ in these populations.  In noncombat 
related PTSD, a much wider variation of trauma exists when compared to combat PTSD (see 
Figure 2). From sexual abuse to car accidents and from kidnapping to severe medical illnesses, 
traumas outside combat zones tend to deal with a large spectrum of incidents.4  While certainly a 
combat setting can be heterogeneous, including firefights, helicopter accidents, or witnessing 
civilian death, most PTSD from a military perspective may arise from direct combat. In fact, 
Hoge et al19 found that there was a direct linear increase in prevalence of PTSD when compared 
to the number of firefights that a soldier was involved in. Furthermore, both being injured in 
combat and killing enemies also increases the likelihood of developing PTSD.19,20,21,16 This 
supports the idea that posttraumatic stress disorder in a military population develops from 
specific combat experiences. The homogeneity of precipitating event is in stark contrast to the 
vast array of possibilities in the civilian population, and this may be an important factor.  
Because of the differences between combat veteran patients and the general population, 
including gender and heterogeneity of traumatic experience, any treatment regime should be 
evaluated with the perspective, that those outside the military are a distinct population.  For this 
reason, the following systematic review of the literature asks, whether, in patients with 
noncombat related PTSD, off-label use of prazosin improves trauma related nightmares and 
sleep disturbances. 
 
METHODS 
An exhaustive search was performed using MEDLINE, CINAHL, PILOTS, and 
PsychINFO databases.   The articles were found in the four databases, using combinations of the 
terms PTSD, Stress Disorder, Prazosin, Alpha Antagonist and Alpha Blocker.   
Inclusion criteria were set to incorporate English language studies that used prazosin to 
treat nighttime symptoms of PTSD in a noncombat, non-military population. Exclusion criteria 
eliminated studies pertaining to combat PTSD, military or veteran population. Non peer-
reviewed ‘Letters to Editor’ were also excluded. 
 
RESULTS 
The comprehensive literature search in the four major databases, in conjunction with the 
specific inclusion and exclusion criteria revealed four studies. These include one randomized 
control trial, one retrospective cohort study, one open-label case series and one case study (see 
Table 1). 
 
Randomized Control Trial 
During 2004 and 2005, Taylor et al10 conducted a crossover style study in which 13 
randomized outpatients with chronic civilian PTSD participated in both the treatment arm and 
the placebo arm of the study. Participants met DSM-IV criteria for PTSD, scored at least 40 on 
the PTSD Checklist-Civilian Version, and had a minimum score of 4 on both the CAPS items #2 
and #13. After excluding 2 subjects who had reported orthostatic dizziness with a test dose, the 
trial subjected the remaining blinded patients to two 3 week periods of both treatment and 
placebo with a 1 week washout period between stages. Medication (or placebo) was initiated at 1 
mg and titrated upward by 1 mg increments over the course of 10 days based on therapeutic or 
adverse effects. The final dose was then maintained for 11 days.10 
Outcomes to be measured in this trial were objective sleep measures including sleep time, 
Rapid Eye Movement (REM) latency, REM duration, and sleep onset latency as well as 
subjective nightmare and overall PTSD symptoms. Adverse events were also monitored and 
discussed for both the treatment and placebo arms of the trial.10 
With a mean prazosin dose achieved of 3.1 +/- 1.3 mg, (vs. mean placebo dose of 3.2 +/- 
1.2 mg), this study showed significant improvement in multiple sleep-related PTSD symptoms in 
the population treated with prazosin. The prazosin group had a longer total sleep time (374 +/- 86 
min vs. 280 +/- 105 min, p < .01), as well as a longer REM sleep time (138 +/- 63 min vs. 97 +/- 70 
min, p < .01).  When compared to the placebo group, those treated with prazosin also had 
decreased sleep REM latency, a measure of the time period between falling asleep and starting 
REM (95 +/- 62 min vs. 30 +/- 20 min, p < .05). In addition to longer REM time, and a faster 
initiation of REM sleep, each REM period had a longer duration on average for the prazosin 
treatment arm of this trial (27 +/- 9 min vs. 18 +/- 9 min, p < .05).  There was no significant 
difference in sleep onset latency between the two groups.10  
In addition to the objective sleep measures, several clinical outcomes were improved in 
the prazosin group, including the CAPS “recurrent distressing dreams” (item #2), Non-nightmare 
Distressed Awakenings (NNDAs), CGI-I scores, the PTSD Dream Rating Scale and PTSD 
Checklist-Civilian Version (PCL-C). The CAPS “difficulty falling asleep/staying asleep (item 
#13) showed an improvement but was not statistically significant. Adverse effects did not differ 
between the placebo group and the treatment group, as dizziness occurred 3 times in each 
group.10 
Conclusions from this trial were that prazosin, in addition to improving clinical PTSD 
sleep related symptoms, provided objective improvements to total sleep time, REM sleep and 
REM duration. The authors also felt that prazosin was well tolerated.10 
 
Retrospective Cohort 
Boyton et al22 conducted a retrospective chart review which analyzed the data from 23 
refugees. All patients from The International Medicine Clinic in Seattle, Washington that had 
been diagnosed with chronic PTSD and had been treated with prazosin between October 2004 
and November 2005 were included in the review.  The cohort, which was made up of 15 females 
and 8 males, included patients from Afghanistan, Albania, Cambodia, Ethiopia, Gambia, Iraq, 
Somalia, and Vietnam.  These patients were exposed to a variety of traumas, including 
kidnapping, sexual abuse and witnessing war atrocities such as death and torture.22     
Changes in nightmare severity were measured through the CAPS “recurrent distressing 
dreams” item before initiation and after 8 weeks of a stable dose of prazosin. The CGI-C was 
used to measure the overall severity of PTSD, after a stable dose of prazosin had likewise been 
given for 8 weeks.22  
The International Medicine Clinic’s standard is to treat patients with an initial dose of 
prazosin of 1 mg, then slowly titrate up until either, symptoms improve, or adverse effects 
become unmanageable.  Results show a statistically significant reduction in CAPS score after 8 
weeks of treatment with a stable dose of prazosin in this population.  The baseline mean was 
6.91 (SD = 0.85) before treatment.  After, the mean CAPS score was 2.61 (SD = 1.67). These 
results indicate that, at baseline, the participants had experienced nightmares daily or almost 
daily, with severe or incapacitating distress, and with difficulty returning to sleep.  The scores 
after 8 weeks of treatment indicated that the subjects experienced nightmares an average of 1-2 
times per week with mild or moderate distress and had regained the ability to fall back asleep. 
Statistically, the improvement in the CAPS score was found to be significantly related to both 
dose and duration of medication received. Overall PTSD severity, as measured by the CGI-C, 
also showed improvement. After treatment, 73.8% of the subjects reported either marked or 
moderate improvement in overall symptoms. Though not objectively measured, the authors 
report that prazosin was well tolerated, with dizziness being the most common reported adverse 
effect. One of the six reported patients to discontinue the medicine after several months did so 
because of dizziness, while the others did so due to significant improvement.22 
 
Open-Label Case Series 
In this open label trial conducted by Taylor et al,23 five outpatients were treated with 
prazosin for their sleep related symptoms of PTSD. They were to be assessed before treatment 
initiation, after two weeks of treatment, and again after 6 weeks of treatment.  Measured 
outcomes included  CAPS-SX Nightmare score and CAPS-SX Insomnia score at these time 
intervals as well as both a CGI-C and a CIC-N score at the completion of 6 weeks of treatment.23 
Patients of this outpatient clinic were identified with the specific requirement that they 
meet DSM-IV criteria for diagnosis of PTSD, a score of at least 80 on the CAPS and a score of 
at least 4 out of 8 on the CAPS-SX. They also had to have PTSD symptoms as their primary 
reason for seeking treatment and have no history of alcohol or substance abuse within the last 6 
months. With these criteria, five consecutive patients were identified. The group included a 53 
year old unemployed woman with a history of abuse and neglect, a 35 year old male carpenter 
who had been severely burned at work, a 53 year old woman exposed to ritual violence and 
forced into prostitution as part of a satanic cult, a 58 year old woman with a history of a life 
threatening pulmonary embolus and a 40 year old nurse who was the victim of abusive parents 
and had to escape her burning house as a child. All patients were started on prazosin at a dose on 
1 mg at bedtime. After 2 weeks, if there was no improvement of symptoms, the dose was 
increased to 2 mg. If necessary, a morning dose was added for daytime symptoms.  Vital signs 
were recorded only if patients reported dizziness.23 
All five patients treated with prazosin had improvement in all measured categories.  The 
frequency and severity of both nightmares and insomnia were reduced after two and six weeks of 
treatment. Furthermore, the CGI-C and CIC-N scores were improved in all five patients. It 
should be noted that while it was not objectively measured, varying degrees of follow up with 
these patients is discussed in this article. Four out of five patients are reported to have continued 
prazosin for several months with sustained benefits. The fifth patient, who had major 
improvement during the trial and no side effects decided to discontinue the prazosin, and has had 
continued improvement without the medication. Authors felt that this patient may have been a 
placebo responder. One participant noted dizziness as an adverse effect.  Otherwise, the authors 
report prazosin as being well tolerated.23 
In a varied outpatient civilian population with diverse individual traumatic experiences, 
such as this one, the conclusions of this small case series were that prazosin was successful in 
improving sleep related symptoms of PTSD. A quick patient response to treatment was felt to 
indicate that the prazosin may be acting directly on the alpha-1 adrenergic receptors. The authors 
recognize however, that several limitations exist, including a small sample size and no placebo 
control, making it difficult to say that the changes experienced are statistically significant. They 
also discussed the possibility that the concomitant use of psychotropic medications in 4 of the 5 
subjects, could have enhanced the effect of prazosin.  Regardless, this small case series was 
thought to offer justification to develop a larger, blinded placebo-controlled trial of prazosin for 
sleep-related PTSD symptoms.23 
 
Case Study 
In the case study by Coupland24, civilian firefighter with PTSD related insomnia 
nightmares was successfully treated with prazosin. The patient met criteria for PTSD but not for 
depression and described severe symptoms including repeated awakenings and frequent 
nightmares. This patient had been subjected to a prior sleep study which ruled out sleep apnea 
but did show awakenings from light sleep as well as decreased total sleep and REM sleep.  The 
patient had tried several other treatment modalities, including psychotherapy, selective serotonin 
reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), and tricyclic 
antidepressants along with combinations of benzodiazepines, and other sedatives.24  
Prazosin 1 mg was initiated at bedtime for one week and then titrated up 1 mg every three 
to four days.  The patient reported initial light-headedness and tiredness upon rising, both of 
which resolved.  He also reported dry mouth in the morning that resolved with breakfast. The 
patient reported improving symptoms at week three, and had a stable dose of 6 mg by week four, 
at which time he reported greatly improved sleep and decrease in nightmares.24 
 
DISCUSSION 
In all four of the studies found with the exhaustive literature search and reviewed above, 
prazosin appears to be both safe and efficacious for the treatment of sleep-related symptoms of 
noncombat PTSD.10, 22-24  
Furthermore, the results of this review demonstrate both the heterogenous nature and 
female prevalence of noncombat PTSD. In previous studies and reviews of this topic, the 
majority of subjects were from a military and male population.1,7,25  In this review 71.4% of the 
subjects in the four studies were female, and the details of the individual trauma varied greatly, 
ranging from decades-old child abuse to severe medical illnesses.  This diverse nature and 
gender distribution highlights the need to analyze this population separately.  Each of the four 
studies was a unique addition to the cumulative result. 
The randomized control trial10 provided an important indicator that, when compared to 
placebo, prazosin shows a significant improvement in sleep-related symptoms of PTSD in this 
population.10 Furthermore, this study is unique in that it measured objective sleep outcomes, 
using the in-home technology of REMView.   
The retrospective study of refugees with PTSD22, while not a trial of traditional civilians, 
met criteria for this systematic review, as the subjects did not have combat-related PTSD and 
were not part of a military or veteran population.22 Furthermore, the heterogeneity of their 
trauma experiences and demographic profile augment the perspective that this systematic review 
sought to achieve, which is a separation from the traditional military population with combat-
PTSD. 
The clear inadequacies of case series and case studies certainly apply to those included in 
this review.  The lack of placebo control, blinding and randomization limit their statistical 
significance.23, 24  However, they provide documented examples of prazosin use for sleep related 
symptoms of PTSD in the civilian population.  Both studies demonstrate a response to the off-
label use of this medication and how it may be a safe alternative to the currently approved PTSD 
medications when patients present with irretractable sleep symptoms such as insomnia and 
nightmares. 
Certainly a limitation of the research is the fact that there exists a limited supply of 
quality studies of prazosin for sleep disturbances in the noncombat PTSD population. 
Furthermore, the only placebo-controlled trial in this review contains a small sample size, as do 
the retrospective cohort and case series. It could be debated whether or not the inclusion of the 
refugee population is a limitation to this review. A cohort of refugees may represent a very 
different population from the general citizenry of the United States.  Their trauma experiences 
may include otherwise unthinkable atrocities such as genocide and civilian death in their war-
torn country of origin. However, an argument could be made that by including such a diverse and 
international population, it is possible to further expand the recommendation for the use of 
prazosin in varied populations. As the exclusion criteria were set up specifically to eliminate 
combat-related PTSD, this study does fit into our review.   
More limits of the existing research are evident. The three studies that were not 
controlled by placebo did not have the burden of establishing that prazosin was superior to 
placebo effect.22-24 The retrospective cohort22, case series23 and case study24 were all non-blinded 
and open label, so bias may have been present in both the patients and evaluators. The exclusion 
of subjects with orthostatic dizziness with a test dose by Taylor et al10 may distort the 
representation of prazosin as being well tolerated in the placebo-controlled study. Also of note, 
Dr. Nick J. Coupland, author of the published case study, declares past research funding by 
Pfizer, the manufacturer of Minipress, the branded form of prazosin.24 
Clearly, there is a need for further randomized, double blind, placebo controlled studies 
of prazosin use for noncombat related PTSD. Sample sizes should be larger and objective sleep 
measures, such as REMView used in the study by Taylor et al, should be continued to be used 
when possible.  
 
 
 
CONCLUSION 
In summary, prazosin shows considerable potential as an agent for the improvement of 
sleep-related symptoms of noncombat related PTSD.  The gender differences and heterogeneity 
of trauma details found in the various studies of this review are in sharp contrast to the male-
dominated, combat-specific PTSD of previous studies and previous systematic reviews. These 
differences provided the impetus for reviewing the literature pertaining to the noncombat 
population. After separating the populations and conducting this review, it does appear that the 
studies’ results are consistent with the findings in military populations with combat PTSD.   
It can be said with confidence that prazosin should be considered for sleep related 
symptoms of noncombat PTSD. This alpha-1 adrenergic receptor antagonist, due to its centrally-
acting properties likely has an impact on the alpha-1 receptors that are often overly stimulated in 
PTSD patients.  Further randomized, placebo-controlled studies with larger sample sizes from 
this population are recommended.  A study by Murray Raskind is in process currently and it is 
expected to be completed in November 2010.26 This is planned to be a larger, randomized 
control study in collaboration with the National Institute of Mental Health and will look at the 
response to prazosin versus placebo in patients receiving an SSRI and psychotherapy.  As the 
FDA currently only approves the SSRIs sertraline and paroxetine for use in PTSD, more of these 
comparison and combination studies should take place to demonstrate efficacy over the standard 
practice and potential as an approved additive medication. 
The above findings have important implications to both mental health clinicians and 
primary care providers.  Even as the United States is currently engaged in war and much 
attention is paid to combat populations, PTSD in civilians is quite prevalent, affecting 7-8% of 
the U.S. population at some time during their lives.3, 27 The general population is subjected to 
noncombat trauma daily here in the U.S., including terrorist attacks, motor vehicle accidents, 
natural disasters, assaults, robberies, kidnappings and severe illnesses, this is a population that 
needs to be recognized as susceptible to posttraumatic stress disorder. Fortunately, when their 
symptoms include sleep-related disturbances, which the majority of PTSD patients experience, a 
clinician can be confident in the safe, efficacious use of prazosin.  
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TABLE 1. Summary Matrix of Reviewed Articles 
 
Study Patients/  
Population 
Intervention Comparison Outcome(s) Jadad 
Score 
Results 
Taylor FB 
 et al10, 2008. 
Randomized 
Placebo-
controlled 
Crossover 
Trial 
Outpatients with 
chronic civilian 
trauma PTSD, 
frequent 
nightmares and 
sleep disturbances. 
n= 13. 
Prazosin, initiated at 
1mg at bedtime, then 
titrated up by 1 mg 
increments every 2-3 
days until therapeutic 
effect. Stable dose 
then maintained for 
11 days. 
Placebo, also 
titrated up over 
same time 
frame and 
intervals as 
intervention 
group. 
CAPS item #2, 
CAPS item #13, 
NNDA’s, CGI-I 
scores, PTSD 
Dream Rating 
scale, PCL-C 
4 Multiple 
objective and 
clinical 
improvements 
Boynton L et 
al22, 2009. 
Retrospective 
cohort study 
Outpatients at 
primary care clinic.  
All patients had 
met DSM-IV 
criteria for PTSD, 
and had been 
treated with 
prazosin.  
n = 23.  
Prazosin, 1 mg at 
bedtime, with the 
dose titrated up until 
either symptoms 
significantly 
improved or adverse 
drug reactions 
developed.  
No comparison CAPS item #2, 
CGI-C scores 
0 Improvement 
in average 
CAPS score 
and 73.8% 
with moderate 
or marked 
Improvement 
in overall 
PTSD 
Taylor F et 
al23, 2002. 
Case Series 
Consecutively 
identified 
outpatients with 
PTSD and sleep 
disturbances. n = 5. 
Prazosin, initiated at 
1 mg at bedtime. As 
needed, dose 
increased to 2 mg at 
bedtime. A morning 
dose was added for 
daytime symptoms if 
needed. 
No comparison CGI-C scores, 
CIC-N scores, 
CAPS-SX 
severity scores 
with insomnia 
and nightmare 
severity sub-
scores 
0 All 5 patients 
showed 
improvement 
in measured 
outcomes 
Coupland 
N24, 2009. 
Case Study 
Civilian firefighter 
with PTSD, 
insomnia, and 
distressing 
nightmares.  
n = 1 
Prazosin, 1 mg at 
bedtime for 1 week, 
then increasing in 1 
mg increments every 
3-4 days to 6 mg as 
stable dose. 
No comparison Subjective 
descriptions of 
restlessness, 
sleep, and 
nightmares 
0 Patient 
reported 
improved 
sleep and 
decreased 
night 
symptoms 
 
 
 
 
 
 
 
 
FIGURE 1.  Gender Distribution  
 
 
 
 
 
 
 
 
 
 
Gender distribution in recent review6, including 
combat-related PTSD
Male 98%
Female 2%
Gender distribution of this systematic review
Male 28.6%
Female 71.4%
FIGURE 2. Heterogeneity of Traumatic Experiences 
 
 
 
 
 
 
 
Traumatic experiences in recent review6
Combat-Related, 97.7%
Severe Medical, .8%
Child Abuse 1.3%
Traumatic experiences in this review
Childhood Sexual Abuse 
11.3%
Childhood Physical Abuse 
9.4%
Adult Assault 5.6%
Rape 13.2%
MVA 1.9%
Witnessing War Atrocities 
15%
Witnessing Family Members 
Killed 11.3%
Torture 15%
Held Captive 15%
 APPENDIX A 
PTSD Checklist – Civilian Version (PCL-C) 
Patient’s Name: ________________________________________________ 
   
No. Response: Not at all (1) 
A little 
bit (2) 
Moderately 
(3) 
Quite a bit 
(4) 
Extremely 
(5) 
1. Repeated, disturbing memories, thoughts, 
or images of a stressful experience from 
the past? 
          
2. Repeated, disturbing dreams of a stressful 
experience from the past? 
          
3. Suddenly acting or feeling as if a stressful 
experience were happening again (as if 
you were reliving it)? 
          
4. Feeling very upset when something 
reminded you of a stressful experience 
from the past? 
          
5. Having physical reactions (e.g., heart 
pounding, trouble breathing, or sweating) 
when something reminded you of a 
stressful experience from the past?  
          
6. Avoid thinking about or talking about a 
stressful experience from the past or avoid 
having feelings related to it? 
          
7. Avoid activities or situations because they 
remind you of a stressful experience from 
the past? 
          
8. Trouble remembering important parts of a 
stressful experience from the past? 
          
9. Loss of interest in things that you used to 
enjoy? 
          
10. Feeling distant or cut off from other 
people? 
          
11. Feeling emotionally numb or being unable           
to have loving feelings for those close to 
you? 
12. Feeling as if your future will somehow be 
cut short? 
          
13. Trouble falling or staying asleep?           
14. Feeling irritable or having angry outbursts?           
15. Having difficulty concentrating?           
16. Being “super alert” or watchful on guard?           
17. Feeling jumpy or easily startled?           
_____________________________________________________________________________________________
___ 
Weathers, F.W., Huska, J.A., Keane, T.M. PCL-C for DSM-IV. Boston: National Center for PTSD – Behavioral 
Science Division, 1991. 
This is a Government document in the public domain. 
 
 
 
 
 
 
 
 
 
 
 
 
